Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.

导出原文传递

翻译打印收藏纠错

作者： Seonggyu,Byeon ^[1] ; Boram,Lee ^[2] ; Woong-Yang,Park ^[2] ; Yoon-La,Choi ^[3] ; Hyun Ae,Jung ^[1] ; Jong-Mu,Sun ^[1] ; Jin Seok,Ahn ^[1] ; Myung-Ju,Ahn ^[1] ; Keunchil,Park ^[1] ; Se-Hoon,Lee ^[4]

作者单位： Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ^[1] Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ^[2] Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea; Department of Pathology and Translational Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ^[3] Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea. Electronic address: shlee119@skku.edu. ^[4]

关键词 Anaplastic lymphoma kinase (ALK)DNA sequencing Epidermal growth factor receptor (EGFR)Non–small-cell lung cancer (NSCLC)Targeted therapy